Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $390 |
| Triangulated Fair Value | $373 |
| 12-mo Scenario PWEV | $394 |
| Implied Return | -4% |
| Forward P/E | 12.9x |
| Market Cap | $87B |
| 52-Week Range | $328 – $555 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate / Deleveraging' (8% weight) — targets $697, +79% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($390) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement Cuts / Labor Inflation' (20%) — targets $173, -56% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 63% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.18 vs analyst floor +0.00 → delta +0.18 (n=30 mgmt / 20 Q&A; 10th pctile across the S&P book, z -1.3).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.18 | +0.00 | +0.18 |
| 2025Q4 | +0.40 | +0.00 | +0.40 |
| 2025Q3 | +0.36 | +0.17 | +0.19 |
| 2025Q2 | +0.45 | +0.20 | +0.25 |
News (last 365d, 1000 articles): avg ticker sentiment +0.19 (bullish 28% / bearish 3%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement Cuts / Labor Inflation' downside ($173) to a 'Bull — Re-Rate / Deleveraging' bull case ($697); the probability-weighted blend (PWEV $394) is +1% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement Cuts / Labor Inflation | 20% | $173 | -56% |
| Volume / Payer-Mix Recession | 17% | $295 | -24% |
| Base — Admissions + Pricing | 35% | $409 | +5% |
| Growth — Volume Recovery / Service-Line | 20% | $552 | +42% |
| Bull — Re-Rate / Deleveraging | 8% | $697 | +79% |
| Probability-Weighted (PWEV) | — | $394 | +1% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement Cuts / Labor Inflation (20%, $173). Structural impairment — reimbursement cuts / labor inflation: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 173.43; probability: 0.2.
- Volume / Payer-Mix Recession (17%, $295). Cyclical downturn — patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage weakens for 1–2 years before normalising. Drivers — implied_target: 294.52; probability: 0.17.
- Base — Admissions + Pricing (35%, $409). Mid-cycle — normalised patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage; disciplined capital allocation; steady returns. Drivers — implied_target: 409.05; probability: 0.35.
- Growth — Volume Recovery / Service-Line (20%, $552). Upside — volume recovery + deleveraging lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 552.22; probability: 0.2.
- Bull — Re-Rate / Deleveraging (8%, $697). Upside tail — sustained tight conditions or a structural re-rate on volume recovery + deleveraging. Drivers — implied_target: 697.43; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $347 | -11% |
| Peer P/E re-rate | multiple | $358 | -8% |
| Peer EV/Revenue re-rate | multiple | $-69 | -118% |
| Scenario PWEV | multiple | $394 | +1% |
| DCF (5-year + terminal) | cash flow + terminal × | $156 | -60% |
| Triangulated (weighted) | — | $373 | -4% |
DCF excluded from the weighted blend — diverges >55% from the Monte-Carlo / scenario core. For a high-leverage equity the per-share DCF (enterprise value less large net debt) is hypersensitive to the terminal multiple; a peer re-rate across heterogeneous margins is apples-to-oranges. Shown above for reference; the blend leans on the multiple-discipline and scenario anchors.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $347 and 42% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (63% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 9.0%, 11x terminal FCF multiple → $156. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 11.82x) implies $358. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Hospital / Dialysis Operations | $76.4B | 100% | 4% | 11% | 13x | 7% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage |
| net_debt_or_cash_b | -48.91 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.07 |
| div_yield | 0.0076 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement cuts / labor inflation |
| upside | volume recovery + deleveraging |
Industry Context — Health Payers Providers
This name sits in the Health Payers Providers as a providers. patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: UNH (managed_care) · CVS (managed_care) · HCA (providers) · ELV (managed_care) · CI (managed_care) · HUM (managed_care) · CNC (managed_care) · DVA (providers) · UHS (providers)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Cost-Trend Spike / Reimbursement-Reform Squeeze | 37% | 37% | |
| Mid-Cycle — Membership & Volume Growth | 35% | 35% | |
| Upside — Margin Recovery / Care-Services | 28% | 28% |
On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_payers_providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $79B | $9B | $6B | $6B | $7B | $6B |
| FY+2 | $83B | $10B | $6B | $6B | $7B | $6B |
| FY+3 | $85B | $10B | $6B | $6B | $7B | $6B |
| FY+4 | $88B | $10B | $6B | $6B | $8B | $5B |
| FY+5 | $90B | $11B | $6B | $6B | $8B | $5B |
| Terminal | — | — | — | — | $8B × 11x | $55B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 7% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 9.0% · Σ PV(FCF) $28B + PV(terminal) $55B = EV $84B; + net cash → equity $35B ÷ diluted shares 0.22B = $156/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $264/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 5% vs WACC 9% → below WACC — the incremental build is value-dilutive.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| UHS | 0.774x | 6.14x | 4% | 11% |
| ELV | 0.527x | 14.35x | 8% | 5% |
| MCK | 0.233x | 17.24x | 5% | 2% |
| CI | 0.353x | 9.29x | 8% | 6% |
| Median | 0.44x | 11.82x | — | — |
Peer-median fwd P/E → $358; EV/Rev → $-69.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| Scenario PWEV | $394 | 50% | $197 |
| Monte Carlo median | $347 | 30% | $104 |
| Peer P/E | $358 | 20% | $72 |
| Triangulated | — | 100% | $373 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 7.7x | 9.3x | 11.0x | 12.6x | 14.3x |
|---|---|---|---|---|---|
| 7% | $106 | $145 | $187 | $227 | $269 |
| 8% | $93 | $131 | $171 | $209 | $250 |
| 9% | $82 | $118 | $156 | $192 | $231 |
| 10% | $70 | $105 | $142 | $176 | $213 |
| 11% | $60 | $93 | $128 | $161 | $196 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $38 | $83 | $127 | $171 | $215 |
| -1.5pp | $47 | $94 | $141 | $188 | $235 |
| +0.0pp | $56 | $106 | $156 | $206 | $256 |
| +1.5pp | $66 | $119 | $172 | $225 | $278 |
| +3.0pp | $75 | $132 | $188 | $245 | $302 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $56 | $256 | $200 |
| Terminal × ±15% | $119 | $194 | $75 |
| Revenue CAGR ±3pp | $127 | $188 | $62 |
| WACC ±1pp | $142 | $171 | $30 |
| FCF conversion ±10% | $156 | $156 | $0 |
Company lever — SoP/share vs Hospital / Dialysis Operations multiple (AI re-rating) (base 13x)
| Multiple | 9.1x | 11.0x | 13.0x | 14.9x | 16.9x |
|---|---|---|---|---|---|
| SoP/share | $2,911 | $3,565 | $4,254 | $4,907 | $5,596 |
Load-Bearing Assumptions
DCF: WACC 9%, terminal multiple 11×, FY+5 revenue $90B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
DCF $156 vs MC median $347 diverge by 55%. Investigate which assumptions differ. A miss on Gross Margin drops the case toward the structural target $173.
Fact / Inference / Speculation
- FACT: Spot $390; 52-week range $328–$555; engine rating HOLD; base-case target $394 (+1%).
- INFERENCE: Triangulated FV $373 (-4%). Gross Margin explains 63% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 63% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $284 (-27% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (63% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).